1. Australia Stocks

  2. •

    Healthcare

  3. •

    Medical - Instruments & Supplies
Nanosonics Limited

Nanosonics Limited

NNCSF
Nanosonics LimitedUS flagOther OTC
2.50
USD
- -
- -
747.05MMarket Cap
Nanosonics Limited
NNCSF
(Other OTC)

Recent

price

2.50

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
- -
0.01
0.05
0.06
0.08
0.08
0.15
0.23
0.2
0.28
0.34
0.34
0.4
0.56
0.57
0.66
Revenue per Share
-0.04
-0.05
-0.02
-0.02
-0.01
-0.02
- -
0.09
0.02
0.05
0.03
0.03
0.01
0.07
0.04
0.07
Basic EPS, GAAP
-0.04
-0.04
-0.03
-0.02
-0.01
-0.02
0.01
0.05
-0.01
-0.01
-0.01
- -
-0.02
-0.01
-0.01
-0.03
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.11
0.06
0.1
0.07
0.06
0.15
0.17
0.25
0.27
0.32
0.35
0.38
0.39
0.46
0.5
0.57
Book Value per Share
0.11
0.06
0.11
0.08
0.08
0.16
0.2
0.29
0.31
0.36
0.41
0.45
0.46
0.54
0.6
0.69
Tangible Book Value per Share
211
227
235
261
263
270
286
297
299
300
300
301
301
301
303
303
Basic Weighted Avg Shares
1
2
12
15
21
22
43
68
61
85
101
102
120
168
172
199
Sales/Revenue/Turnover
-1,295.81
-622.3
-56.58
-60.08
-33.36
-40.85
-4.24
16.07
1.93
13.9
9.05
3.88
-4.12
6.48
0.44
4.49
Operating Margin (%)
1
1
1
1
1
1
1
1
1
2
4
4
6
7
8
8
Depreciation Expense
-8
-11
-5
-6
-3
-5
- -
26
6
14
10
9
4
20
13
21
Net Income, GAAP
- -
- -
- -
- -
- -
- -
10.29
- -
- -
19.18
18.64
21.9
- -
7.93
0.11
7.23
Effective Tax Rate (%)
-1,071.04
-499.07
-38.04
-38.71
-12.12
-24.58
0.29
38.75
9.48
16.08
10.06
8.42
3.13
11.87
7.56
10.39
Profit Margin (%)
22
13
33
29
27
41
56
72
77
89
107
123
122
149
166
186
Working Capital
- -
- -
7
8
8
- -
1
1
1
- -
1
1
9
8
6
4
LT Debt
24
14
26
22
20
45
57
87
94
110
124
136
139
164
182
210
Total Equity
- -
- -
- -
- -
- -
- -
-2.91
- -
- -
9.23
6.24
2.32
- -
6.1
0.41
4.05
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
1.33
- -
- -
15.51
10.21
7.84
- -
14.7
9.05
12.87
Return on Capital (%)
-42.75
-62.52
-25.28
-27.15
-14.89
-19.53
0.27
41.92
7.34
15.41
10.09
7.79
3.21
15.43
8.91
12.7
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
17.45%
11.2%
15.21%
Free Cash Flow
94.15%
109.44%
246.56%
Net Income, GAAP
2,165.6%
76.84%
59.39%
Sales/Revenue/Turnover
27.57%
15.39%
15.95%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
168
2024
- -
- -
- -
- -
172
2025
- -
- -
- -
- -
199

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.07
2024
- -
- -
- -
- -
0.04
2025
- -
- -
- -
- -
0.07

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
InnerScope Hearing Technologies, Inc. (INND)
Medeon Biodesign, Inc. (6499.TWO)
JINS HOLDINGS Inc. (JNDOF)
Hamilton Thorne Ltd. (HTL.TO)
Maxigen Biotech Inc. (1783.TW)
Analogic Corporation (ALOG)
Business
Nanosonics Limited (ASX:NAN; OTC:NNCSF) develops, manufactures and commercialises infection prevention and control solutions for the healthcare industry, with a focus on automated high-level disinfection technologies for ultrasound probes and other medical instruments. The company offers the trophon ultrasound probe disinfector product family, including trophon EPR, a patented sonicated mist technology for high-level disinfection of endocavitary and surface probes; trophon2, which provides enhanced protection across high-level disinfection cycles with AcuTrace digital record-keeping and workflow compliance features; trophon3, the next-generation device launched following US FDA clearance in 2025; AuditPro nanosonics, an infection control workflow compliance management tool; and CORIS, an innovative instrument reprocessing platform for endoscopes and other devices, which received US FDA De Novo clearance in March 2025 and entered controlled market release. It also provides related consumables, accessories, service contracts, NanoCare device warranties and maintenance, and training via Nanosonics Academy. Nanosonics operates in Australia, North America, Europe, the United Kingdom, the Middle East and Asia Pacific, targeting hospitals, imaging centres and clinics to combat healthcare-acquired infections. Founded in 2000 and headquartered in Macquarie Park, New South Wales, Australia, the company employs approximately 466 people and generates the majority of its revenue from recurring consumables and service streams alongside capital equipment sales. In fiscal year 2025, Nanosonics reported revenue of AUD 198.6 million, a gross margin of 78.2 per cent and increased capital expenditures to AUD 8.7 million for manufacturing expansions, including new facilities for CORIS supply chain and consumables production in Australia and the USA. Recent developments include the establishment of seven new patent families; implementation of a new ERP system, enhanced cybersecurity with ISO 27001 re-certification and cloud infrastructure for customer connectivity; expanded service operations; US FDA approvals for trophon3 and CORIS; a planned launch of trophon2 Plus; reaffirmed fiscal 2026 revenue guidance with 11-14 per cent growth; and the announcement of an up to AUD 20 million share buy-back program in November 2025, alongside board changes such as the appointment of Gerard Dalbosco as independent non-executive director and Lisa McIntyre not seeking re-election.

Company News

APIChat

  • seekingalpha.com

    Nanosonics Limited (NNCSF) Q2 2026 Earnings Call Transcript

  • defenseworld.net

    Nanosonics (OTCMKTS:NNCSF) Shares Down 7.8% – Here’s What Happened

  • seekingalpha.com

    Nanosonics Limited (NNCSF) Shareholder/Analyst Call Transcript

  • seekingalpha.com

    Nanosonics Limited (NNCSF) Q4 2025 Earnings Call Transcript

  • seekingalpha.com

    Nanosonics Limited (NNCSF) Q2 2025 Earnings Call Transcript

  • seekingalpha.com

    Nanosonics Limited (NNCSF) Q4 2023 Earnings Call Transcript

  • seekingalpha.com

    Nanosonics Limited (NNCSF) Q2 2023 Earnings Call Transcript